# US 2024/0197959 A1 · Implantable Device and Therapeutic System with Active Oxygenation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197959 A1
- Document ID: US20240197959A1
- Status: Published application
- Kind: A1
- Application number: 18/288,092
- Filed: 2022-04-25
- Published: 2024-06-20
- Earliest claimed: 2021-04-27
- Assignees: Sanofi
- Applicants: Sanofi
- Inventors: Lionel Vedrine; Christina Laskar; Pradeep Dhal; Craig Harvey Nelson; Mark Robson Humphries; Carys Eleri Lee; Nicholas Oliver Harding
- Web page: https://patentgrep.com/patent/US20240197959A1

## CPC

- A61F 2/022: {Artificial gland structures using bioreactors (hemodialysis A61M1/16; hemofiltration A61M1/34; other extracorporeal blood treatment A61M1/36)}
- A61L 27/3895: {using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions}
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 38/28: Insulins
- A61L 27/227: {Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24}
- A61L 27/34: Macromolecular materials
- A61L 27/3804: {characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells}
- A61L 27/50: Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61M 37/00: Other apparatus for introducing media into the body (for reproduction or fertilisation A61B17/425; apparatus for iontophoresis or cataphoresis A61N1/30); Percutany, i.e. introducing medicines into the body by diffusion through the skin (salt baths A61H33/04)
- A61F 2250/0023: differing in porosity
- A61L 2300/10: containing or releasing inorganic materials
- A61L 2300/11: Peroxy compounds, peroxides, e.g. hydrogen peroxide
- A61L 2300/414: Growth factors
- A61L 2300/43: Hormones, e.g. dexamethasone
- A61L 2300/64: Animal cells
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

An implantable device for providing a therapeutic agent includes a container configured to contain multiple cells capable of producing the therapeutic agent within an interior region of the container and a substance capable of reacting to generate oxygen for the multiple cells within the interior region of the container. The container defines first pores defined by an interior wall portion of the container and second pores defined by an exterior wall portion of the container. The first pores have a first average size that (i) allows passage of the therapeutic agent through the first pores and (ii) prevents passage of immune cells through the first pores. The second pores have a second average size that is larger than the first average size, and the second pores are sized to promote vascularization along the exterior wall portion.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

An implantable device for providing a therapeutic agent, the implantable device comprising:
a container configured to contain a plurality of cells capable of producing the therapeutic agent within an interior region of the container, the container defining:
first pores defined by an interior wall portion of the container, the first pores having a first average size that (i) allows passage of the therapeutic agent through the first pores and (ii) prevents passage of immune cells through the first pores, and
second pores defined by an exterior wall portion of the container, the second pores having a second average size that is larger than the first average size, and the second pores being sized to promote vascularization along the exterior wall portion; and
a substance capable of reacting to generate oxygen for the plurality of cells within the interior region of the container.

### Claim 17 (depends on 16)

The implantable device of claim 16, wherein the implantable device has an external surface area to volume ratio of about 200 to about 5,000.

### Claim 18 (depends on 16)

The implantable device of claim 16, wherein the second average size of the second pores locates vasculature along the second pores, and wherein the second average size of the second pores allows passage of the therapeutic agent through the exterior wall portion to the vasculature.

### Claim 19 (depends on 16)

The implantable device claim 16, wherein the first pores have first widths in a range of about 10 nm to about 400 nm, and wherein the second pores have second widths in a range of about 2 μm to about 60 μm.

### Claim 20 (depends on 16)

The implantable device of claim 16, wherein the interior region has width is in a range of about 100 μm to about 2 mm.

### Claim 21 (depends on 16)

The implantable device of claim 16, wherein the interior region is wide enough to accommodate multiple cells of the plurality of cells across a plane that is perpendicular to a central axis of the container.

### Claim 22 (depends on 16)

The implantable device of claim 16, wherein the container has a wall thickness in a range of about 1 μm to about 100 μm.

### Claim 23 (depends on 16)

The implantable device of claim 16, wherein the container comprises a tube, and wherein the tube has a linear configuration, a spiral configuration, or a helical configuration.

### Claim 24 (depends on 23)

The implantable device of claim 23, wherein the tube is a first tube, wherein the implantable device further comprises a second tube disposed inside of the first tube, and wherein the first and second tubes together define an annular lumen for containing the plurality of cells.

### Claim 25 (depends on 24)

The implantable device of claim 24, wherein the implantable device comprises a plurality of particles comprising the substance, and wherein the plurality of particles is disposed within a core region of the second tube.

### Claim 26 (depends on 16)

The implantable device of claim 16, further comprising a plurality of particles comprising the substance, wherein the plurality of particles are part of a coating applied to an inner surface of the interior wall portion.

### Claim 27 (depends on 16)

The implantable device of claim 16, wherein the exterior wall portion is coated with a growth factor that promotes vascularization, and:
wherein the growth factor is covalently linked to the exterior wall portion, and/or
wherein the growth factor is electrostatically bound to the exterior wall portion, and/or
wherein the growth factor is site-specifically bound to the exterior wall portion, and/or
wherein the growth factor is selected from the group consisting of: vascular endothelial growth factor (VEGF), placenta derived growth factor (PDGF), transforming growth factor beta (TGFβ), and fibroblast growth factor (FGF), and/or
wherein the growth factor is vascular endothelial growth factor (VEGF), placenta derived growth factor (PDGF), transforming growth factor beta (TGFβ), fibroblast growth factor (FGF), or a combination thereof, and/or
wherein the growth factor is vascular growth factor (VEGF).

### Claim 28 (depends on 16)

The implantable device of claim 16, further comprising the plurality of cells contained within the interior region of the container.

### Claim 29 (depends on 28)

The implantable device of claim 28, wherein the plurality of cells are beta cells, and wherein the therapeutic agent comprises insulin.

### Claim 30 (depends on 16)

The implantable device of claim 16, further comprising one or more additional containers associated with the container, wherein each of the one or more additional containers contains an additional plurality of cells.

### Claim 31 (depends on 16)

The implantable device of claim 16, wherein the substance is hydrogen peroxide, carbamide peroxide, magnesium peroxide, or calcium peroxide.

### Claim 32 (depends on 16)

The implantable device of claim 16, wherein the container comprises a tubular wall that comprises the interior and exterior wall portions, wherein the tubular wall further defines third pores arranged radially between the first and second pores, and wherein the third pores have a third average size that is greater than the first average size and less than the second average size.

### Claim 33 (depends on 32)

The implantable device of claim 32, wherein pores defined by the tubular wall gradually increase in size from an interior surface of the tubular wall to an exterior surface of the tubular wall.

### Claim 34 (depends on 16)

The implantable device of claim 16, wherein the interior wall portion comprises a tubular member and the exterior wall portion comprises a coating that surrounds the tubular member, and wherein the tubular member has a first material formulation and the coating has a second material formulation that is different from the first material formulation.

### Claim 35

A therapeutic system comprising:
an implantable device for providing a therapeutic agent, the implantable device configured to be implanted subcutaneously along a skin region, and the implantable device comprising:
a container configured to contain a plurality of cells capable of producing the therapeutic agent within an interior region of the container, the container defining:
first pores defined by an interior wall portion of the container, the first pores having a first average size that (i) allows passage of the therapeutic agent through the first pores and (ii) prevents passage of immune cells through the first pores, and
second pores defined by an exterior wall portion of the container, the second pores having a second average size that is larger than the first average size, and the second pores being sized to promote vascularization along the exterior wall portion; and
a substance capable of reacting to generate oxygen for the plurality of cells within the interior region of the container; and
an accessory device configured to cooperate with the implantable device for promoting delivery of oxygen to the plurality of cells.
